Evogene (EVGN) fair value: what the stock is really worth
We calculate from audited financials what Evogene is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jun 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Evogene for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.
How to read this chart
60‑month range $0.3900 – $37.00 · fair‑value band $0.7140 – $1.18 · the $0.4240 price screens below the $0.9435 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 23, 2026.
Follow Evogene in your weekly email
Every Wednesday you see whether Evogene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications.
Show more
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Stock analysis
Evogene (EVGN) currently trades at $0.4240, while our model-based Fair Value estimate is $0.9435, implying the stock looks roughly 55.1% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 3 models at a data quality of 80/100, which puts the evidence level at low.
Scenario range: $0.7140 (bear) to $1.18 (bull), the price of $0.4240 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Evogene reported revenue of $3.9M in FY2025 versus $930K in FY2021, a compound +42.7%/yr. Reported net income was −$8.5M in FY2025.
Key figures
Market cap $6.4M · P/S ratio 3.45 · EPS (TTM) $−1.70 · Return on equity −172% · Return on assets (EBIT) −49.8% · Operating margin −952% · Revenue (TTM) $1.8M · Revenue growth (YoY) −86.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 71% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 123%, EVGN screens cheaper than that median.
Notify me when EVGN reaches fair value
Put EVGN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−30.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.9%
Start year 2020 (pandemic). Over 10 years: −10.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,386.0% (2020) → −364.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside+109% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−33% · Bottom 25%
Growth and dividend
Revenue growth−86% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)3.45× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Evogene Fair Value". https://www.fairvalue-calculator.com/stock/EVGN
Frequently asked questions
Is Evogene (EVGN) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.9435 versus a price of $0.4240, about +123% upside (undervalued).
What is the fair value of EVGN?
Our model-based fair value for Evogene is $0.9435 (as of Jun 23, 2026), built from audited fundamentals. The current price: $0.4240.
What is the quality score of EVGN?
Evogene has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evogene (EVGN)?
Our model-based price target is the fair value of $0.9435 (as of Jun 23, 2026) from 3 valuation models. Cautious scenario $0.7140, optimistic scenario $1.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Evogene stock forecast for 2026?
Our models put fair value at $0.9435, about +123% upside versus a price of $0.4240 (undervalued). Cautious scenario $0.7140, optimistic scenario $1.18. The calculation is refreshed regularly with new filings.
What is the revenue of Evogene (EVGN)?
Evogene reported trailing-twelve-month revenue of about $1.8M (latest available figure, as of Jun 23, 2026).
What is the intrinsic value of Evogene (EVGN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evogene it is $0.9435 per share (as of Jun 23, 2026), against a price of $0.4240. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Evogene stock overvalued or undervalued in 2026?
As of Jun 23, 2026, EVGN trades below its calculated fair value: price $0.4240, fair value $0.9435, a gap of about +123% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVGN?
No. The price is what the market pays today ($0.4240); the fair value is what the company's own numbers justify ($0.9435). For Evogene the two are $0.5195 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evogene worth?
The market values Evogene at about $6.4M (market capitalisation, as of Jun 23, 2026). Per share that is $0.4240; our models calculate a fair value of $0.9435 per share.
What do the bullish and bearish scenarios say about EVGN?
Our models span a range for Evogene: cautious scenario $0.7140, base $0.9435, optimistic $1.18 per share (as of Jun 23, 2026, price $0.4240). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Evogene (EVGN)?
Balance-sheet figures for Evogene (as of Jun 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is EVGN from its 52-week high?
Evogene trades at $0.4240, about 71% below its 52-week high of $1.46 and 9% above the low of $0.3900 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9435 is for.
Which stocks are comparable to Evogene?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evogene stock attractive at the current price?
The data as of Jun 23, 2026: price $0.4240, calculated fair value $0.9435 (+123%), Quality Score 24/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EVGN calculated?
We run Evogene through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.9435, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Evogene currently trades 123 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evogene (EVGN)?
The closing price on Sep 24, 2026 was $0.4240. Our model-based fair value is $0.9435, about +123% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evogene right now?
The large discount to fair value meets weak quality (24/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.7140). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Evogene
How large is the market capitalisation of Evogene (EVGN)?
The market capitalisation of Evogene is $6.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evogene (EVGN)?
The price-to-sales ratio of Evogene is 3.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evogene (EVGN)?
Earnings per share at Evogene are $−1.70. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Evogene (EVGN)?
The return on equity (ROE) of Evogene is −172% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evogene (EVGN)?
On an EBIT basis the return on assets of Evogene is −49.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evogene (EVGN)?
The operating margin of Evogene is −952% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evogene (EVGN)?
Revenue at Evogene is growing −86.3% versus a year earlier (3y avg +32.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Evogene (EVGN) generate?
The free cash flow of Evogene is −$13.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Evogene (EVGN) hold?
Evogene holds more cash than debt, $10.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Evogene in the live analysis
One click puts Evogene on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jun 23, 2026